FY2025 · ended Dec 31, 2025 · Revenue $858,000, +34.9% YoY · Filed Mar 16, 2026
Rallybio Corporation (RLYB) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $858,000 and a net loss of $9.0 million. As of Sep 30, 2026 it held $90.7 million in cash and investments and $0 in total debt.
Revenue (TTM)
$434,000
-35.6% vs year-ago TTM
Net income (TTM)
$26.81M
+289.2% vs year-ago TTM
Operating cash flow (TTM)
$30.99M
+188.5% vs year-ago TTM
Free cash flow
$-49.28M
+18.2% vs prior year
EPS (TTM)
$4.65
+646.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
5.29M
-87.3% vs prior year
Net cash
$90.69M
as of Sep 30, 2026
Operating margin
-5580.9%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RLYB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1739410
- Former names
- Rallybio Holdings, LLC (until Jun 7, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $858,000 | $636,000 | — | — | — |
| Operating income | -$33.1M | -$60.5M | -$78.9M | -$67.9M | -$45.6M |
| Net income | -$9.0M | -$57.8M | -$74.6M | -$66.7M | -$47.0M |
| Diluted EPS | -$1.59 | -$10.61 | -$1.84 | -$2.09 | — |
| Operating cash flow | -$29.8M | -$49.3M | -$60.3M | -$57.3M | -$45.5M |
| Free cash flow | — | -$49.3M | -$60.3M | -$57.3M | -$45.9M |
| Total assets | $62.3M | $68.1M | $115.6M | $180.4M | $182.2M |
| Total liabilities | $4.3M | $6.5M | $9.4M | $11.1M | $6.6M |
| Stockholders' equity | $58.0M | $61.7M | $106.2M | $169.3M | $175.6M |
| Cash and investments | $54.7M | $65.5M | $109.9M | $169.0M | $175.3M |
| Total debt | $176,000 | $154,000 | $392,000 | $555,000 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Shareholder vote results, Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Oct 27, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 26, 2026 | Oct 25, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 9, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change in control, Officer or director change, Regulation FD disclosure
|
Jun 1, 2026 | May 31, 2026 |
All 308 Rallybio Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.